Onyx’s Kyprolis Heads To ODAC With Open-label Trial; Will Desperation Outweigh Doubts?
This article was originally published in The Pink Sheet Daily
Onyx is relying on a single open-label single-arm Phase IIb trial of Kyprolis (carfilzomib) in patients with relapsed and refractory myeloma, which resulted in an overall response rate of 24%
You may also be interested in...
Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.